title: [In vitro antibacterial activity of a new oral cephalosporin, ceftibuten. Results of a multicenter study].
abstract: Minimal inhibitory concentration (MIC) of ceftibuten (CBT) were evaluated by agar dilution for 1,416 bacterial strains isolated in 5 hospitals. For Enterobacteriaceae, MIC 50 and 90% were respectively (micrograms/ml): (I) Naturally non beta-lactamase producing species: E. coli 0.12-0.5, Shigella 0.06-0.12 and Salmonella 0.03-0.12, P. mirabilis 0.16-0.03. (II) Chromosomal penicillinase producing species: K. pneumoniae 0.03-0.5 and K. oxytoca 0.03-0.06. (III) Chromosomal cephalosporin producing species: E. cloacae and C. freundii 1- greater than 128: S. marcescens 0.25-2; indole + Proteus 0.06-0.12. Activity of CBT was not modified on plasmid mediated penicillinase producing strains; however, CBT was inactive on cephalosporinase hyperproducing strains, and its activity was variably reduced on broad spectrum beta-lactamases producing strains. CBT was inactive on P. aeruginosa (MIC greater than or equal to 32) and on A. baumannii (8- greater than 128). Haemophilus and Gonococci, regardless on beta-lactamase production status, were very susceptible to CBT (MIC 50 and 90%: 0.06-0.5 and 0.016-0.06); it is the same situation for Meningococci; B. catarrhalis was generally inhibited by 0.03 to 2 (strains susceptible to penicillin G) and 0.12 to 16 (strains resistant to penicillin G). CBT was inactive on Staphylococci. Enterococci and Streptococci B were generally resistant; Streptococci A, C, G were inhibited by low concentrations: 0.06 to 1 (MIC 50 and 90%: 0.25-0.5), whereas MIC for other Streptococci 0.12 to 128 (MIC 50 and 90%: 8-128) and for Pneumococci were 0.25 to 16 (4-8). These antibacterial properties particularly against Enterobacteriaceae placed CBT in excellent position among oral cephalosporins.
authors.affiliation: Service de Bactériologie, CHU Henri Mondor, Créteil.
authors.forename: C J
authors.initials: CJ
authors.lastname: Soussy
authors.forename: M
authors.initials: M
authors.lastname: Meyran
authors.forename: M
authors.initials: M
authors.lastname: Chanal
authors.forename: M E
authors.initials: ME
authors.lastname: Reverdy
authors.forename: M D
authors.initials: MD
authors.lastname: Kitzis
authors.forename: E
authors.initials: E
authors.lastname: Derlot
mesh_terms: D000150:Acinetobacter / Q000187:drug effects*; D000284:Administration, Oral; D001421:Bacteria, Anaerobic / Q000187:drug effects; D000077722:Ceftibuten; D002511:Cephalosporins / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004755:Enterobacteriaceae / Q000187:drug effects*; D006190:Haemophilus / Q000187:drug effects*; D066298:In Vitro Techniques; D001936:Moraxella catarrhalis / Q000187:drug effects; D009343:Neisseria / Q000187:drug effects; D011549:Pseudomonas / Q000187:drug effects*; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects
chemical_list: D002511:Cephalosporins; D000077722:Ceftibuten
vernacular_title: Activité antibactérienne in vitro d'une nouvelle céphalosporine orale, le ceftibutène. Résultats d'une étude multicentrique.